Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Aptorum Group Limited (APM)

    Price:

    1.30 USD

    ( - -0.03 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    APM
    Name
    Aptorum Group Limited
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    1.300
    Market Cap
    9.285M
    Enterprise value
    17.749M
    Currency
    USD
    Ceo
    Chung Yuen Huen
    Full Time Employees
    1
    Ipo Date
    2018-12-18
    City
    London
    Address
    17 Hanover Square

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    76.562B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    ADMA Biologics, Inc.

    VALUE SCORE:

    11

    Symbol
    ADMA
    Market Cap
    4.706B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    122.616B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -4.485
    P/S
    0
    P/B
    0.400
    Debt/Equity
    0.151
    EV/FCF
    -8.406
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.223
    Debt/assets
    0.193
    FUNDAMENTALS
    Net debt/ebidta
    -0.400
    Interest coverage
    -11.799
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.000
    Capex to revenue
    0
    Capex to depreciation
    0.000
    Return on tangible assets
    -0.114
    Debt to market cap
    0.375
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    -0.081
    P/CF
    -7.778
    P/FCF
    -7.795
    RoA %
    -11.410
    RoIC %
    -8.547
    Gross Profit Margin %
    0
    Quick Ratio
    2.984
    Current Ratio
    2.984
    Net Profit Margin %
    0
    Net-Net
    -0.220
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.167
    Revenue per share
    0
    Net income per share
    -0.290
    Operating cash flow per share
    -0.167
    Free cash flow per share
    -0.167
    Cash per share
    0.387
    Book value per share
    1.932
    Tangible book value per share
    1.932
    Shareholders equity per share
    3.246
    Interest debt per share
    0.507
    TECHNICAL
    52 weeks high
    7.490
    52 weeks low
    0.672
    Current trading session High
    1.380
    Current trading session Low
    1.280
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.188k
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.245
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.003
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.203
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.199
    logo

    Country
    IL
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -3.426
    logo

    Country
    AU
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.131
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.126
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -14.664
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.711
    DESCRIPTION

    Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

    NEWS
    https://images.financialmodelingprep.com/news/diamir-biosciences-and-aptorum-group-announce-two-abstracts-accepted-20251119.jpg
    DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference

    globenewswire.com

    2025-11-19 08:00:00

    NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, taking place December 1-4, 2025, in San Diego, CA, and online.

    https://images.financialmodelingprep.com/news/andean-precious-metals-corp-apmca-q3-2025-earnings-call-20251112.jpg
    Andean Precious Metals Corp. (APM:CA) Q3 2025 Earnings Call Transcript

    seekingalpha.com

    2025-11-12 11:21:34

    Andean Precious Metals Corp. ( APM:CA ) Q3 2025 Earnings Call November 12, 2025 9:00 AM EST Company Participants Amanda Mallough Alberto Morales - Founder, CEO & Executive Chairman Yohann Bouchard - President & Director Juan Sandoval - Chief Financial Officer Dom Kizek Conference Call Participants Omeet Singh - SCP Resource Finance LP, Research Division Allison Carson - Desjardins Securities Inc., Research Division Ben Pirie - Atrium Research Corporation Presentation Operator Hello, and welcome to the Andean Precious Metals Third Quarter Conference Call and Webcast. [Operator Instructions] I would now like to turn the conference over to Amanda Mallough, Director of Investor Relations.

    https://images.financialmodelingprep.com/news/aptorum-group-limited-announces-up-to-6-million-registered-20251010.jpg
    Aptorum Group Limited Announces Up To $6 Million Registered Direct Offering

    globenewswire.com

    2025-10-10 09:54:00

    $2 million upfront with up to additional $4 million of potential aggregate gross proceeds upon the exercise in full of warrants

    https://images.financialmodelingprep.com/news/as-part-of-the-planned-merger-with-diamir-biosciences-20251009.jpg
    As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives

    globenewswire.com

    2025-10-09 08:55:00

    NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp.

    https://images.financialmodelingprep.com/news/andean-precious-metals-recordhigh-goldsilver-prices-pave-the-way-20250923.jpg
    Andean Precious Metals: Record-High Gold-Silver Prices Pave The Way For A Mid-Tier Producer

    seekingalpha.com

    2025-09-23 05:43:03

    Andean Precious Metals Corp. (APM:CA) is rated a Buy, driven by strong financials and robust growth strategies in gold and silver production. APM:CA benefits from rising precious metal prices, solid free cash flow, and a healthy balance sheet, supporting ongoing expansion and share buybacks. San Bartolomé's long-term ore agreement and Golden Queen's exploration program underpin production growth and extended mine life for APM:CA.

    https://images.financialmodelingprep.com/news/aptorum-group-and-diamir-biosciences-to-present-at-the-20250905.jpg
    Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference

    globenewswire.com

    2025-09-05 08:00:00

    NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced a joint presentation at the H.C. Wainwright 27th Annual Global Investment Conference (https://hcwevents.com/annualconference/).

    https://images.financialmodelingprep.com/news/why-is-nanocap-aptorum-stock-rallying-on-thursday-20250821.jpg
    Why Is Nano-Cap Aptorum Stock Rallying On Thursday?

    benzinga.com

    2025-08-21 11:39:34

    Aptorum shares trade higher on 168.16 million volume vs 3.25 million average. DiamiR gains CLEP approval for APOE Genotyping test in New York.

    https://images.financialmodelingprep.com/news/diamir-biosciences-and-aptorum-group-announce-new-york-state-20250821.jpg
    DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test

    globenewswire.com

    2025-08-21 07:07:00

    NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping test from the New York State Department of Health (NYSDOH). This milestone allows DiamiR to offer its validated APOE Genotyping molecular testing in a variety of biological samples, such as blood, buccal swab, saliva, and tissue, through its Clinical Laboratory Improvement Amendments (CLIA) certified, College of American Pathologists (CAP) accredited clinical laboratory by licensed healthcare providers in New York State and nationwide.

    https://images.financialmodelingprep.com/news/andean-precious-metals-corp-anpmf-q2-2025-earnings-call-20250813.jpg
    Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-13 12:13:50

    Andean Precious Metals Corp. (OTCQX:ANPMF) Q2 2025 Earnings Conference Call August 13, 2025 9:00 AM ET Company Participants Alberto Morales - Founder, CEO & Executive Chairman Amanda Mallough - Corporate Participant Dom Kizek - Corporate Participant Juan Carlos Sandoval - Chief Financial Officer Yohann Bouchard - President & Director Conference Call Participants Allison Carson - Desjardins Securities Inc., Research Division Ben Pirie - Atrium Research Corporation Justin Chan - SCP Resource Finance LP, Research Division Operator Good morning, and welcome to Andean Precious Metals Second Quarter 2025 Results Conference Call. As a remainder, all participants are in the listen-only-mode.

    https://images.financialmodelingprep.com/news/aptorum-group-limited-regains-compliance-with-nasdaqs-minimum-bid-20250804.jpg
    Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement

    globenewswire.com

    2025-08-04 08:15:00

    NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq's minimum bid price requirement.

    https://images.financialmodelingprep.com/news/aptorum-group-limited-and-diamir-biosciences-enter-into-definitive-20250716.jpg
    Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement

    globenewswire.com

    2025-07-16 08:38:00

    NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.

    https://images.financialmodelingprep.com/news/aptorum-group-limited-announces-receipt-of-nasdaq-notification-regarding-20250416.jpg
    Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

    globenewswire.com

    2025-04-16 12:27:00

    Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).

    https://images.financialmodelingprep.com/news/cpkc-and-lanco-groupmijack-sell-panama-canal-railway-company-20250402.jpg
    CPKC and Lanco Group/Mi-Jack sell Panama Canal Railway Company to APM Terminals

    prnewswire.com

    2025-04-02 08:00:00

    CALGARY, AB , April 2, 2025 /PRNewswire/ - Canadian Pacific Kansas City Limited (TSX: CP) (NYSE: CP) (CPKC) today said CPKC and the Lanco Group/Mi-Jack have sold the Panama Canal Railway Company (PCRC) to APM Terminals, a global terminal operator and an independent division of A.P. Moller - Maersk.

    https://images.financialmodelingprep.com/news/andean-precious-metals-corp-apm-opens-the-market-20250109.jpg
    Andean Precious Metals Corp. (APM) Opens the Market

    newsfilecorp.com

    2025-01-09 11:09:00

    Toronto, Ontario--(Newsfile Corp. - January 9, 2025) - Alberto Morales, Executive Chairman and Chief Executive Officer, Andean Precious Metals Corp. ("Andean Precious Metals" or the "Company") (TSX: APM), and his team joined Dean McPherson, Head, Business Development, Global Mining, Toronto Stock Exchange (TSX), to open the market to celebrate the Company's graduation to Toronto Stock Exchange. Cannot view this video?

    https://images.financialmodelingprep.com/news/synology-launches-activeprotect-simplifying-enterprise-data-protection-with-unmatched-20250108.jpg
    Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability

    businesswire.com

    2025-01-08 11:30:00

    BELLEVUE, Wash.--(BUSINESS WIRE)--Synology launches the ActiveProtect series a unified enterprise backup solution set to disrupt the current data backup market.